A recent headline claimed that most Alzheimer’s cases could be prevented by targeting a single gene. But what does the research behind this bold statement really show? In this episode, we unpack a large genetic study examining the role of the APOE gene in Alzheimer’s disease. With help from Emeritus Professor James Vickers, we explore genetic risk versus genetic destiny, what population‑level findings mean for individuals, and how close — or far — this research is from real‑world treatments. The focus is on understanding the evidence without overstating hope or ignoring uncertainty. 

Based on:
 The Guardian (Jan 2026) – “Alzheimer’s therapies should target a particular gene, researchers say” 

Listener Reflection Questions

1. How did hearing more about how genetic risk is calculated change the way you interpreted the headline about APOE and Alzheimer’s?
2. What’s the difference between research that identifies risk and research that leads to treatment — and why does that distinction matter here?
3. When you see strong claims about genes and disease, what questions could you now ask to better judge what the research is really saying?

Brought to you by the ISLAND Project and Wicking Dementia Research and Education Centre at the University of Tasmania. To continue the discussion and for more information visit https://island.mooc.utas.edu.au or email [email protected]